The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Banner BG

PRMT5 Signaling

See how Bayer is investigating PRMT5 signaling across the oncology pipeline

Explore the investigational compounds, tumor types, and clinical trials associated with this area of research.

PRMT5 Signaling

  • Arginine-methylated proteins, which play a role in several cellular processes, are formed by the catalytic activity of protein arginine methyltransferase 5 (PRMT5)1,2

  • Under physiological conditions, PRMT5 is inhibited by methylthioadenosine (MTA), and MTA is catalyzed to adenosine and 5-methylthioribose-1-phosphate by the enzyme methylthioadenosine phosphorylase (MTAP).1 However, the MTAP gene is deleted in up to 30% of tumors, which increases MTA levels in cancer cells1-3

  • Currently, Bayer is evaluating a PRMT5 inhibitor that selectively targets MTAP-deficient cancer cells where MTA is elevated, sparing normal cells that have low levels of MTA1,4

Tumor Types

Gastrointestinal cancer (pancreatic)
Solid tumors

Related Compound

PRMT5 inhibitor (BAY 3713372)

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.